GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.

about

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.

Item

http://www.wikidata.org/entity/Q41147408

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en-gb

type

Item

label

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en-gb

prefLabel

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en-gb

P1154

2-s2.0-85026321540

http://www.w3.org/2001/XMLSchema#string

P1433

Trials

P1476

GA101 (obinutuzumab) monocLona ...... I randomised controlled trial.

@en

P2093

Andy C Rawstron

http://www.w3.org/2001/XMLSchema#string

Anna Hockaday

http://www.w3.org/2001/XMLSchema#string

Claire Dimbleby

http://www.w3.org/2001/XMLSchema#string

David Phillips

http://www.w3.org/2001/XMLSchema#string

Dena R Howard

http://www.w3.org/2001/XMLSchema#string

Jamie B Oughton

http://www.w3.org/2001/XMLSchema#string

Kathryn McMahon

http://www.w3.org/2001/XMLSchema#string

Lucy McParland

http://www.w3.org/2001/XMLSchema#string

Talha Munir

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Nonparametric Estimation from Incomplete Observations

A multiple testing procedure for clinical trials

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.

Chronic lymphocytic leukaemia--moving towards cure?

Optimal two-stage designs for phase II clinical trials.

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

P2888

s13063-017-2107-0

P304

353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13063-017-2107-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jamie B Oughton

Peter Hillmen

Laura Collett

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090899275

http://www.w3.org/2001/XMLSchema#string

P6366

2736670139

http://www.w3.org/2001/XMLSchema#string

P698

28747208

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial

P932

5530563

http://www.w3.org/2001/XMLSchema#string

P953

121126/